Induction of posterior vitreous detachment (PVD) by non-enzymatic reagents concentrating on vitreous collagen liquefaction in addition to vitreoretinal adhesion
Induction of posterior vitreous detachment (PVD) by pharmacologic vitreolysis has been largely tried via using enzymatic reagents. Ocriplasmin has been the one FDA-approved medical reagent to this point. A number of hostile results of ocriplasmin have emerged, nevertheless, and the seek for various PVD-inducing reagents continues.
Since i) collagen kinds an necessary structural element of the vitreous, and ii) sturdy vitreo-retinal adhesions exist between the cortical vitreous and the interior limiting membrane (ILM) of the retina, an efficient PVD-inducing reagent would require each, vitreous liquefaction, and concurrent dehiscence of vitreoretinal adhesion, with out being poisonous to retinal cells. We designed a mixture of two reagents to realize these two aims; a triple helix-destabilizing collagen binding area (CBD), and a fusion of RGD (integrin-binding) tripeptide with CBD (RCBD) to facilitate separation of posterior cortical vitreous from retinal floor.
Based mostly on in vitro, ex-vivo, and in vivo experiments, we present {that a} mixture of CBD and RCBD shows potential for secure pharmacologic vitreolysis. Our findings assume significance in gentle of the truth that artificial RGD-containing peptides have already been used for inhibition of tumor cell invasion. Proteins akin to variants of collagen binding domains might have prolonged therapeutic makes use of sooner or later.
Description: LEC is a CC chemokine that can signal through the CCR8 and CCR1 receptors. It is expressed in the liver, spleen, and thymus. LEC is chemotactic towards monocytes and lymphocytes but not neutrophils. Recombinant human LEC is an 11.2 kDa protein containing 97 amino acid residues, including the four conserved cysteine residues present in CC chemokines.
Description: LEC is a CC chemokine that can signal through the CCR8 and CCR1 receptors. It is expressed in the liver, spleen, and thymus. LEC is chemotactic towards monocytes and lymphocytes but not neutrophils. Recombinant human LEC is an 11.2 kDa protein containing 97 amino acid residues, including the four conserved cysteine residues present in CC chemokines.
Description: LEC is a CC chemokine that can signal through the CCR8 and CCR1 receptors. It is expressed in the liver, spleen, and thymus. LEC is chemotactic towards monocytes and lymphocytes but not neutrophils. Recombinant human LEC is an 11.2 kDa protein containing 97 amino acid residues, including the four conserved cysteine residues present in CC chemokines.
Description: CCL16 Human Recombinant produced in E.Coli is a non-glycosylated, Polypeptide chain containing 97 amino acids and having a molecular mass of 11.2 kDa. ;The CCL16 is purified by proprietary chromatographic techniques.
Description: LEC is a CC chemokine that can signal through the CCR8 and CCR1 receptors. It is expressed in the liver, spleen, and thymus. LEC is chemotactic towards monocytes and lymphocytes but not neutrophils. Recombinant human LEC is an 11.2 kDa protein containing 97 amino acid residues, including the four conserved cysteine residues present in CC chemokines.
Description: LEC is a CC chemokine that can signal through the CCR8 and CCR1 receptors. It is expressed in the liver, spleen, and thymus. LEC is chemotactic towards monocytes and lymphocytes but not neutrophils. Recombinant human LEC is an 11.2 kDa protein containing 97 amino acid residues, including the four conserved cysteine residues present in CC chemokines.
Description: Chemokine (C-C motif) ligand 16 (CCL16) is a small cytokine belonging to the CC chemokine family that is known under several pseudonyms, including Liver-expressed chemokine (LEC) and Monotactin-1 (MTN-1). This gene is one of several cytokine genes clustered on the q-arm of chromosome 17. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. The cytokine encoded by this gene displays chemotactic activity for lymphocytes and monocytes but not for neutrophils. This cytokine also shows a potent myelosuppressive activity and suppresses proliferation of myeloid progenitor cells. The expression of this gene is upregulated by IL-10.
Description: A Monoclonal antibody against Human HCC-4 / Liver Expressed Chemokine (LEC) - With BSA and Azide. The antibodies are raised in Mouse and are from clone LEC66. This antibody is applicable in E
Monoclonal HCC-4 / Liver Expressed Chemokine (LEC) Antibody - With BSA and Azide, Clone: LEC67
Description: A Monoclonal antibody against Human HCC-4 / Liver Expressed Chemokine (LEC) - With BSA and Azide. The antibodies are raised in Mouse and are from clone LEC67. This antibody is applicable in E
Monoclonal HCC-4 / Liver Expressed Chemokine (LEC) Antibody - Without BSA and Azide, Clone: LEC66
Description: A Monoclonal antibody against Human HCC-4 / Liver Expressed Chemokine (LEC) - Without BSA and Azide. The antibodies are raised in Mouse and are from clone LEC66. This antibody is applicable in E
Monoclonal HCC-4 / Liver Expressed Chemokine (LEC) Antibody - Without BSA and Azide, Clone: LEC67
Description: A Monoclonal antibody against Human HCC-4 / Liver Expressed Chemokine (LEC) - Without BSA and Azide. The antibodies are raised in Mouse and are from clone LEC67. This antibody is applicable in E
MBP/MBL ELISA Kit| Rat Mannma Binding Protein/Mannan Binding Lec
Description: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human Anti-MBL. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Human Anti-MBL. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Human Anti-MBL, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human Anti-MBL in the samples is then determined by comparing the OD of the samples to the standard curve.
Human Anti-MBL(Anti-Mannose Binding Lectin Antibody) ELISA Kit
Description: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human Anti-MBL. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Human Anti-MBL. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Human Anti-MBL, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human Anti-MBL in the samples is then determined by comparing the OD of the samples to the standard curve.
Human Anti-Mannose Binding Lectin Antibody (Anti-MBL) ELISA Kit
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Mannose Binding Lectin Antibody (Anti-MBL) in serum, plasma and other biological fluids.
Human Anti-Mannose Binding Lectin Antibody (Anti-MBL) ELISA Kit
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Mannose Binding Lectin Antibody (Anti-MBL) in serum, plasma and other biological fluids.
Human Anti-Mannose Binding Lectin Antibody (Anti-MBL) ELISA Kit
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Mannose Binding Lectin Antibody (Anti-MBL) in serum, plasma and other biological fluids.
Human Anti-Mannose Binding Lectin Antibody (Anti-MBL) ELISA Kit
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Mannose Binding Lectin Antibody (Anti-MBL) in serum, plasma and other biological fluids.
Human Anti-Mannose Binding Lectin Antibody (Anti-MBL) ELISA Kit
Description: Enzyme-linked immunosorbent assay based on the Competitive Inhibition method for detection of Human Anti-Mannose Binding Lectin Antibody (Anti-MBL) in samples from Serum, plasma and other biological fluids with no significant corss-reactivity with analogues from other species.
Human Anti-Mannose Binding Lectin Antibody (Anti-MBL2) ELISA Kit
Description: A competitive Inhibition ELISA kit for detection of Anti-Mannose Binding Lectin Antibody from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids.
Description: LECT2, also known as chondromodulin II, is a 16 kDa secreted protein preferentially expressed in the liver. It has significant sequence homology with chicken myb-induced myeloid protein 1 (mim-1). LECT2 is a neutrophil chemotactic protein, and it also stimulates chondrogenic growth. The amino acid sequence of human LECT2 shares 86% and 82% identity with bovine and mouse LECT2, respectively.
Applicability of ninhydrin as a fluorescent reagent for estimation of teicoplanin in human plasma utilizing salting-out assisted liquid-liquid extraction approach
The applicability of ninhydrin, a broadly used derivatizing reagent, for dedication of teicoplanin (TEIC) in its pure kind, pharmaceutical vials, and in human plasma was investigated. The introduced spectrofluorimetric methodology was based mostly on a condensation response between ninhydrin and the first amine group current in TEIC (within the presence of phenylacetaldehyde) to supply a extremely fluorescent product detected at 460 nm (λex ,390 nm). Calibration plots have been constructed within the focus vary 60-600 ng mL-1 with an excellent correlation coefficient of 0.9998 and a low detection restrict of 10.84 ng mL-1 .
The tactic was subjected to a bioanalytical validation research based on US-FDA suggestions. The proposed methodology was utilized for evaluation of TEIC in business vials with excessive restoration outcome 101.88 ± 1.11%. As well as, the methodology was utilized effectively for detection of TEIC in human plasma utilizing salting-out assisted liquid-liquid extraction approach (SALLE) with a restoration vary from 96.71 ± 1.08% to 97.71 ± 0.86%. SALLE is an efficient strategy used for extraction of TEIC from human plasma with out interferences utilizing ammonium sulphate. The proposed methodology is extremely really helpful to observe TEIC in medical laboratory samples and therapeutic drug monitoring programs.
Analysis of a brand new thromboplastin reagent STA-NeoPTimal on a STA R Max analyzer for the measurement of prothrombin time, worldwide normalized ratio and extrinsic issue ranges
Introduction: We aimed toward evaluating the efficiency of a brand new prothrombin time (PT) reagent (STA-NeoPTimal) with two different PT reagents (STA-Neoplastine R and STA-Neoplastine CI Plus) and the reference PT reagent utilized in our laboratory (ReadiPlasTin).
Strategies: Analysis consisted in intra- and interassay precision evaluation, dedication of sensitivity to unfractionated heparin (UFH) or enoxaparin in spiked samples and to direct oral anticoagulants (DOACs) in sufferers (n = 43). Methodology comparability of the four PT reagents, issue II, V, VII and X assays was examined on regular (n = 20) and irregular samples: VKA (n = 47), preoperative (n = 23), liver failure (n = 12) and burned sufferers (n = 37).
Outcomes: Analytical efficiency met producers’ standards for all reagents. All PT reagents gave correlation coefficients >0.eight and even >0.9 in lots of conditions. In some VKA samples, variations ≥ 0.5 INR models have been present in samples inside and above therapeutic ranges. For burned sufferers, PT correlations have been good however with some minimal bias (<5.0%) whereas issue assays gave very constant outcomes (R > .eight and primarily >0.9). As anticipated, poor responsiveness of the PT to DOAC concentrations was noticed with all 4 assays.
Conclusion: The STA-NeoPTimal confirmed comparable efficiency to ReadiPlasTin, making it appropriate for VKA management, detection of things II, V, VII, X deficiency and evaluation of liver illness coagulopathy. Nevertheless, for sufferers receiving VKA, some important variations have been noticed. We confirmed the shortcoming of the PT assay to detect residual DOAC concentrations. Lastly, burned sufferers outcomes confirmed that recombinant thromboplastins have been much less delicate to issue deficiencies compared to extraction thromboplastins.
Description: B7-1(CD80) and B7-2, together with their receptors CD28 and CTLA4, constitute one of the dominant costimulatory pathways that regulate T and B cell responses. Although both CTLA4 and CD28 can bind to the same ligands, CTLA4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the downregulation of the immune response. B7-1 is expressed on activated B cells, activated T cells, and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be upregulated through interferon gamma. B7-1 and B7-2 are both members of the Immunoglobulin superfamily.
Description: B7-1 (CD80) and B7-2, together with their receptors CD28 and CTLA4, constitute one of the dominant costimulatory pathways that regulate T and B cell responses. Although both CTLA4 and CD28 can bind to the same ligands, CTLA4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the downregulation of the immune response. B7-1 is expressed on activated B cells, activated T cells, and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be upregulated through interferon gamma. B7-1 and B7-2 are both members of the Immunoglobulin superfamily.
Description: CD80 Human Recombinant produced in Sf9 Insect cells is a single, glycosylated polypeptide chain containing 216 amino acids (35-242a.a.) and having a molecular mass of 24.9kDa (Molecular size on SDS-PAGE will appear at approximately 28-40kDa).;CD80 is expressed with an 8 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
Description: CD80 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD80 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD80 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD80 appears to be expressed later in the immune response than CD86. CD80 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells.
Description: CD80 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD80 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD80 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD80 appears to be expressed later in the immune response than CD86. CD80 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells.
Description: Human CD80 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest.
Description: Description of target: The protein encoded by this gene is a membrane receptor that is activated by the binding of CD28 or CTLA-4. The activated protein induces T-cell proliferation and cytokine production. This protein can act as a receptor for adenovirus subgroup B and may play a role in lupus neuropathy.;Species reactivity: Human;Application: ELISA;Assay info: ;Sensitivity: < 33pg/mL
Description: Description of target: The protein CD80(Cluster of Differentiation 80) is a molecule found on activated B cells and monocytes which provides a costimulatory signal necessary for T cell activation and survival. It is also known as B7-1. The cDNA for B7-1 predicts a type I membrane protein, i.e., one synthesized with a signal peptide that is cleaved upon translocation across the endoplasmic membrane. The protein is predicted to contain 2 extracellular domains structurally similar to those of Ig, a hydrophobic transmembrane region, and a short cytoplasmic domain. The CD80 and CD86 genes encode B7-1 and B7-2, respectively, which are structurally similar members of the immunoglobulin superfamily expressed on a variety of hematopoietic cell types. B7-1 and B7-2 provide a costimulatory signal to T cells by interacting with CD28 and CTLA4.;Species reactivity: Human;Application: ELISA;Assay info: ;Sensitivity: <10pg/ml